Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Crohn's Disease · Ulcerative Colitis (UC)

AbbVie

AbbVie clinical programs — 32 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
1 Waukegan Road, North Chicago, Illinois 60064, US HQ
60,084 Employees
NMPA registrant Type
Company details
Status
Public
HQ
1 Waukegan Road, North Chicago, Illinois 60064, US
Employees
60,084
Programs
41
Drugs
32
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

AbbVie projects

32 ClinicalTrials.gov programs sponsored by AbbVie.

AbbVie has 32 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

32 programs

Clinical programs

  1. Adalimumab

    AbbVie

    Juvenile Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  2. Adalimumab

    AbbVie

    Psoriatic Arthritis

    phase 3 small molecule completed

    1 trial

  3. BOTOX

    AbbVie

    Masseter Muscle Prominence

    phase 3 small molecule completed

    1 trial

  4. Cariprazine

    AbbVie

    Bipolar I Disorder

    phase 3 small molecule completed

    1 trial

  5. Glecaprevir/Pibrentasvir

    AbbVie

    Hepatitis C Virus (HCV)

    phase 3 small molecule completed

    2 trials

  6. Levodopa-Carbidopa Intestinal Gel (LCIG)

    AbbVie

    Advanced Parkinson's Disease

    phase 3 small molecule completed

    1 trial

  7. Lutikizumab

    AbbVie

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  8. Matching Placebo for Upadacitinib

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  9. Mirvetuximab Soravtansine

    AbbVie

    Epithelial Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  10. Mirvetuximab soravtansine plus Bevacizumab

    AbbVie

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  11. Placebo

    AbbVie

    Ulcerative Colitis (UC)

    phase 3 small molecule completed

    2 trials

  12. Placebo

    AbbVie

    Psoriatic Arthritis

    phase 3 mab active

    1 trial

  13. Placebo

    AbbVie

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  14. Placebo for Adalimumab

    AbbVie

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  15. Placebo to Upadacitinib

    AbbVie

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  16. Risankizumab

    AbbVie

    Palmoplantar Pustulosis (PPP)

    phase 3 small molecule completed

    1 trial

  17. Risankizumab

    AbbVie

    Psoriasis

    phase 3 small molecule active

    1 trial

  18. Standard of Care

    AbbVie

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  19. Telisotuzumab Adizutecan

    AbbVie

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. Upadacitinib

    AbbVie

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  21. Upadacitinib

    AbbVie

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  22. Upadacitinib

    AbbVie

    Atopic Dermatitis

    phase 3 small molecule active

    3 trials

  23. Upadacitinib

    AbbVie

    Crohn's Disease

    phase 3 small molecule active

    2 trials

  24. Upadacitinib

    AbbVie

    Spondyloarthritis

    phase 3 small molecule completed

    1 trial

  25. Upadacitinib

    AbbVie

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  26. Upadacitinib (ABT-494)

    AbbVie

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  27. Venetoclax

    AbbVie

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  28. adalimumab

    AbbVie

    Pyoderma Gangrenosum

    phase 3 small molecule completed

    1 trial

  29. placebo for risankizumab

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  30. placebo for risankizumab IV

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  31. risankizumab

    AbbVie

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  32. risankizumab IV

    AbbVie

    Ulcerative Colitis (UC)

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does AbbVie have?

32 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.